Abstract: Over the past decade, with the steadily increasing nuclear power around the world and the rapid growth of nuclear technology applications in healthcare, especially radiopharmaceutical therapy with isotopes emitting α particles, the research on actinide element chemistry has made significant progress in both fundamental research and applications. To further understand the physicochemical properties of actinide elements, the focus of experimental research has been on clarifying the proportion of covalence in the bonding of actinide ions with ligands, and on discriminating actinide ions by the size which is compatible to the spatial cavity of multi-dentate ligands. In theoretical computation, the results on optimizing the coordination geometry of actinide complexes with improved pseudo potentials for the relativistic effects of inner electrons in actinide ions and the progress in calculations on excitation states related to the spectroscopy properties of actinide complexes are worth noting. Application-oriented coordination chemistry is the area of great production, especially the research on separation and alpha-radiotherapy with encouraging results, and the research on element actinium is an eye-catching focus and hotspot. Overall, the efforts on actinium research over the past decade have exceeded the total of previous years, while compared with other actinide elements, the attention to actinium in the past decade has surpassed that of all other actinide elements combined. This paper mainly includes two parts: first, a summary of the spectroscopic properties of actinide ions and the corresponding research methods, as well as the challenges in computation chemistry for actinide elements and the ideas for improving computation strategy; second, a specific introduction to the research progress and results from research on actinium, and a prospect for the production and application of actinium isotopes related to radiopharmaceutical therapy. Due to the larger ionic radius of Ac(Ⅲ) compared to other Ln/An(Ⅲ), the stability of the complex of DOTA with Ac(Ⅲ) is much lower than with Lu(Ⅲ). DOTA is the gold standard for bonding other Ln(Ⅲ) and An(Ⅲ) in nuclear medicine, but it does not present great binding capability with Ac(Ⅲ) and the labeling kinetics are also relatively slow. To address this short back, a new macrocyclic chelator, Macropa, has been developed to replace DOTA. Because of its unique structure, the coordination ability of Macropa with La(Ⅲ) which is the best surrogate for Ac(Ⅲ), can compete with DOTA, and does not suffer from the slow coordination kinetics associated with DOTA.